Book ChapterDOI
Nonparametric Estimation from Incomplete Observations
Edward L. Kaplan,Paul Meier +1 more
Reads0
Chats0
TLDR
In this article, the product-limit (PL) estimator was proposed to estimate the proportion of items in the population whose lifetimes would exceed t (in the absence of such losses), without making any assumption about the form of the function P(t).Abstract:
In lifetesting, medical follow-up, and other fields the observation of the time of occurrence of the event of interest (called a death) may be prevented for some of the items of the sample by the previous occurrence of some other event (called a loss). Losses may be either accidental or controlled, the latter resulting from a decision to terminate certain observations. In either case it is usually assumed in this paper that the lifetime (age at death) is independent of the potential loss time; in practice this assumption deserves careful scrutiny. Despite the resulting incompleteness of the data, it is desired to estimate the proportion P(t) of items in the population whose lifetimes would exceed t (in the absence of such losses), without making any assumption about the form of the function P(t). The observation for each item of a suitable initial event, marking the beginning of its lifetime, is presupposed. For random samples of size N the product-limit (PL) estimate can be defined as follows: L...read more
Citations
More filters
Journal ArticleDOI
Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics.
Claudio G. Brunstein,Jeffrey S. Miller,Qing Cao,David H. McKenna,Keli L. Hippen,Julie M. Curtsinger,Todd E. DeFor,Bruce L. Levine,Carl H. June,Pablo Rubinstein,Philip B. McGlave,Bruce R. Blazar,John E. Wagner +12 more
TL;DR: There was a reduced incidence of grade II-IV aGVHD with no deleterious effect on risks of infection, relapse, or early mortality and the results set the stage for a definitive study of UCB Treg to determine its potency in preventing allogeneic aGV HD.
Journal ArticleDOI
A systematic review of the incidence of biological and technical complications in implant dentistry reported in prospective longitudinal studies of at least 5 years
TL;DR: Implant loss was most frequently described (reported in about 100% of studies), while biological complications were considered in only 40-60% and technical complications in only 60-80% of the studies, indicating that data on the incidence of biological andTechnical complications may be underestimated and should be interpreted with caution.
Journal ArticleDOI
Phase III Trial of Standard-Dose Intravenous Cisplatin Plus Paclitaxel Versus Moderately High-Dose Carboplatin Followed by Intravenous Paclitaxel and Intraperitoneal Cisplatin in Small-Volume Stage III Ovarian Carcinoma: An Intergroup Study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group
Maurie Markman,Brian N. Bundy,David S. Alberts,Jeffrey M. Fowler,Daniel L. Clark-Pearson,Linda F. Carson,Scott Wadler,Joshua Sickel +7 more
TL;DR: An experimental regimen including moderately high-dose IV carboplatin followed by IP paclitaxel and IV cisplatin yielded a significant improvement in progression-free survival when compared with a standard regimen of IV cis Platin and pac Litaxel.
Journal ArticleDOI
Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study.
Michael J. Keating,Ian W. Flinn,Vinay K. Jain,Jacques-Louis Binet,Peter Hillmen,John C. Byrd,Maher Albitar,Lee R. Brettman,Pedro Santabarbara,Bret Wacker,Kanti R. Rai +10 more
TL;DR: Alemtuzumab induced significant responses in patients with relapsed or refractory B-cell chronic lymphocytic leukemia with clinical benefit in the majority and with acceptable toxicity in a high-risk group.
Journal ArticleDOI
Prognostic discrimination in "good-risk" chronic granulocytic leukemia
Joseph E. Sokal,EB Cox,Michele Baccarani,Tura S,German A. Gomez,Judith E. Robertson,CY Tso,Thomas J. Braun,Bayard D. Clarkson,Francisco Cervantes +9 more
TL;DR: The prognostic significance of disease features recorded at the time of diagnosis was examined among 813 patients with Philadelphia chromosome- positive, nonblastic chronic granulocytic leukemia (CGL) collected from six European and American series, and it should be possible to identify a lower risk group of patients with a 2-yr survival of 90%, subsequent risk averaging somewhat less than 20%/yr and median survival of 5 yr.
References
More filters
Journal ArticleDOI
Survival Curve for Cancer Patients Following Treatment
Joseph Berkson,Robert P. Gage +1 more
TL;DR: A simple function, in terms of two physically meaningful parameters, has been evolved, which fits survivorship data very well and can be used to compare succinctly the mortality of two groups, different in respect of treatment, type of cancer, or other characteristics.
Journal ArticleDOI
An analysis of some failure data
TL;DR: The rationale and statistical techniques employed in the analysis of some failure data obtained from operations performed by machines and people are summarized and the agreement between theory and data is evaluated.